Authors
Latest:
Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic DisordersThis systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.
Latest:
Simplifying Vaccine Access Translates to Better UptakeInvestigators evaluated strategies to simplify the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.
Latest:
Candida auris: Coming Soon to a Facility Near You?Epidemiologic and clinical lessons for the uninitiated.
Latest:
Multidrug Resistance in a Patient With HIVIn this case study, clinicians review a challenging case.
Latest:
Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid AntibioticRifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Latest:
The Next Generation of COVID-19 Vaccines and BoostersWill there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Latest:
Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur ActThe pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
Latest:
That’s Not Appropriate: A Look at Antibiotic Prescribing Post DischargeExtending antimicrobial stewardship programs to transition of care and discharge may prove beneficial to reduce unnecessary antibiotic use.
Latest:
Health Equity is Essential to Overcoming Antimicrobial ResistanceThe antimicrobial resistance (AMR) crisis stems from natural microbial adaptation and the lack of new antimicrobials in development. Vulnerable populations worldwide, including within the US, are disproportionately affected, exacerbating the spread of resistance.
Latest:
New Insights into Fungal Infections: Resistance, Mortality, and Environmental RisksThe latest fungal-focused edition of the CDC's Emerging Infectious Diseases highlights the global spread of antifungal resistance, Aspergillus infections, and Histoplasma detection in Spain.
Latest:
Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUAA review of the data and circumstances that led to authorization in children ages 5 to 11 years.
Latest:
Opposing Forces During COVID-19: Perspective From the ICUConflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Latest:
Opposing Forces During COVID-19: Perspective From the ICUConflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Latest:
Lifting the Medical and Economic Burden of AMR in the USThis bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.
Latest:
Febrile Finesse: Are We Employing Appropriate Empiric Coverage in Patients With Neutropenic Fever?Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.
Latest:
SHARE the Responsibility of Antibiotic Stewardship With Our PatientsHow pharmacists can use shared decision-making to improve antibiotic use.
Latest:
Updates in the Treatment of Mycobacterium TuberculosisThe latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Latest:
Key Takeaways on FMTs in the Treatment of CDIExperts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Latest:
The Next Generation of COVID-19 Vaccines and BoostersWill there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Latest:
Lessons in Resilience: What HIV Teaches Us About COVID-19Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
Latest:
Second-Generation Antifungal Aims to Address Invasive Fungal DiseaseScynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.
Latest:
Expanded Treatment Options for Multi-Drug Resistant Infections in ChildrenIn the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Latest:
How Do You Measure the Success of Your Stewardship Program?The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.
Latest:
First-Hand Insights into Treating Hepatitis C in PregnancyCatherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Latest:
SURE1 and REASSURE Trials Paved Way for FDA Approval of OrlynvahCorey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Latest:
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care TherapyA small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Latest:
Cautionary Tale Associated in Trial With Rare Error in Cox RegressionInflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost the company some of its data for its investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Latest:
Pandemic Preparedness: How Immunomics Technology is Leading the WayThe COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.
